Month: June 2020

Pratteln, Switzerland, June 2, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed a long-term, open-label extension study of 24 months duration with vamorolone in patients with Duchenne muscular dystrophy (DMD). Including 6 months treatment in the preceding study, ReveraGen has now obtained safety and efficacy data with vamorolone over a period of 2.5 years in 41 boys with DMD.Eligible for enrolment into the now completed 24-month long-term, open-label extension study (VBP15-LTE, clinicaltrials.gov ID: NCT03038399) were boys who had previously completed the 6-month dose escalation study VBP15-003 (clinicaltrials.gov ID: NCT02760277). Data from this VBP15-003 study in comparison to natural history study data demonstrated dose-dependent improvement in timed function tests. Vamorolone...

Pratteln, Schweiz, 2. Juni 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Partnerunternehmen ReveraGen Biopharma Inc. eine langfristige, offene Anschlussstudie von 24 Monaten Dauer mit Vamorolone bei Patienten mit Duchenne-Muskeldystrophie (DMD) abgeschlossen hat. Zusammen mit einer 6-monatigen Behandlungsdauer in einer vorangehenden Studie hat ReveraGen nun Daten zur Verträglichkeit und Wirksamkeit mit Vamorolone über einen Zeitraum von 2.5 Jahren bei 41 Knaben mit DMD erhoben.Teilnahmeberechtigt für die jetzt abgeschlossene 24-monatige langfristige, offene Anschlussstudie (VBP15-LTE, clinicaltrials.gov ID: NCT03038399) waren Knaben, die zuvor die 6-monatige Studie VBP15-003 mit ansteigender Dosierung (clinicaltrials.gov ID: NCT02760277) abgeschlossen hatten. Im Vergleich zu Daten einer Studie zum natürlichen Krankheitsverlauf...

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinomaTecentriq combination improved overall survival and progression-free survival compared to the previous standard of careApplication approved under FDA’s Project Orbis initiative and Real-Time Oncology Review pilot programmeBasel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on...

Munich/Antwerp, 2 June 2020, 7:00 am CESTVGP NV (“VGP”), the Antwerp-based European provider of high-quality logistics and semi-industrial real estate, and Allianz have expanded their strategic partnership by entering an agreement in respect of a new 50:50 joint venture for the development of VGP Park München.The managerial and governance setup of the new partnership is similar to the existing two joint ventures between the two partners. VGP will serve the new joint venture as its sole asset, property and development manager.  Allianz Real Estate will manage the joint venture on behalf of Allianz group companies. Contrary to the two existing joint ventures which concentrate on the acquisition of income-generating assets developed by VGP, this new joint venture will initially be focussed on the development of VGP Park München.Once fully...

München/Antwerpen, 2 juni 2020, 7:00 CETVGP NV (“VGP”), de in Antwerpen gevestigde pan-Europese ontwikkelaar, beheerder en eigenaar van logistiek en semi-industrieel vastgoed, en Allianz hebben hun strategisch partnerschap uitgebreid door een overeenkomst te sluiten met betrekking tot een nieuwe 50:50 joint venture voor de ontwikkeling van VGP Park München.De management- en bestuursstructuur van het nieuwe partnerschap is vergelijkbaar met de twee bestaande joint ventures tussen de twee partners. VGP zal de nieuwe joint venture als enige asset-, vastgoed- en ontwikkelingsmanager dienen. Allianz Real Estate zal de joint venture namens de bedrijven van de Allianz-groep beheren. In tegenstelling tot de twee bestaande joint ventures die zich concentreren op de verwerving van door VGP reeds ontwikkelde prime assets, zal deze nieuwe...

VANCOUVER, British Columbia, June 02, 2020 (GLOBE NEWSWIRE) — via NetworkWire – Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF) (the “Company”) announces $5.3M in revenues in its third quarter, compared to $2.5M in the previous year’s third quarter and $5.5M in the second quarter. Revenues were slightly less than last quarter even though business was affected by Covid-19. Even with these unforeseen circumstances Wildflower was able to operate with a net gain of $101,435 compared to a loss of $(1,019,862) Q3 2019.Highlights for the quarter ending March 31, 2020 (with comparisons to the prior year’s quarter except as otherwise noted) include the following:Revenues of $5,301,762 (Q3 2019: $2,547,230), including sales in British Columbia’s provincially regulated cannabis market, US nationwide e-commerce sales, nationwide US wholesale...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) — Standard Uranium Ltd. (“Standard Uranium” or the “Company”) (TSX-V: STND) is pleased to announce that it has entered into a letter agreement (the “Agreement”) with Red Cloud Securities Inc. (“Red Cloud”) as lead agent on behalf of a syndicate of agents (collectively, the “Agents”) and has filed and obtained a receipt for a preliminary short form prospectus (the “Preliminary Prospectus”) with the securities regulators in each of the Provinces of Canada other than the Province of Québec, pursuant to which the Company proposes to complete a public offering (the “Offering”) of units for gross proceeds of C$3,000,000 (the “Offered Securities”). Closing of the Offering is expected...

CALGARY, Alberta, June 01, 2020 (GLOBE NEWSWIRE) — Saturn Oil & Gas Inc. (“Saturn” or the “Company”) (TSX.V: SOIL) (FSE: SMK) announced today that due to the impact of the global COVID-19 pandemic, it will postpone the filing of its interim financial statements (“Financial Statements”) and management’s discussion and analysis (“MD&A”) for the first quarter period ended March 31, 2020, until no later than June 8, 2020.The Company will be relying on the exemption provided in BC Instrument 51-515 Temporary Exemption from Certain Corporate Finance Requirements (and similar exemptions provided by other Canadian securities regulators).Until the Company has filed its Financial Statements and MD&A, members of the Company’s Board, management and other insiders are subject to an insider trading...

VANCOUVER, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) — Fortress Technologies Inc. (“Fortress” or the “Company”) (TSXV: FORT), a well-capitalized company currently evaluating emerging opportunities in technology sectors, reports its results of operations for the first quarter and three month period ended March 31, 2020 (“Q1 2020”) and for the fourth quarter and full year ended December 31, 2019 (“YE 2019”). For the full condensed consolidated interim financial statements and management discussion & analysis for the Q1 2020 and YE 2019, please visit the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. Three-Months Ended March 31, 2020“We are pleased to report a net income of $640,263 for the first quarter of 2020, which results in an earnings per share of $0.01...

REDWOOD CITY, Calif., June 01, 2020 (GLOBE NEWSWIRE) — Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $84.00 per share, before deducting underwriting discounts and commissions (3,750,000 of which are being sold by Guardant Health and 7,750,000 are being sold by SoftBank Investment Advisers). The public offering was increased from the previously announced offering size of 10,000,000 shares of common stock. In addition, Guardant Health and SoftBank Investment Advisers have granted the underwriter a 30-day option to purchase up to...